Improvements in medical therapy and prognosis for patients with HFrEF following the 2021 ESC HF Guidelines: a nationwide registry study

17 May 2025 (08:00 - 12:45)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Doctor Kristian Berge

Akershus University Hospital - AHUS, Nordbyhagen (Norway)

6 More presentations in this session

Presentation thumbnail

Discussant panel

Presentation thumbnail

Treatment uptake in the era of quadruple pharmacotherapy for heart failure with reduced ejection fraction: from prescriptions to patient adherence and persistence

Doctor F. Lindberg (Stockholm, SE)

Presentation thumbnail

Contemporary patient characterization and implementation of medical therapy for heart failure across the ejection fraction spectrum: the OPTIPHARM-HF registry

Doctor R. Inciardi (Brescia, IT)

Presentation thumbnail

Timing of cardiac resynchronization therapy after optimal medical therapy in patients with heart failure: temporal trends, predictors and association with outcomes

Doctor A. Villaschi (Milan, IT)

Presentation thumbnail

Cardiac resynchronization therapy in heart failure: a target trial emulation study

Doctor C. Basile (Stockholm, SE)

Access the full session

Session thumbnail

Latest registries and observational studies

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025

You may be interested in

Congress Presentation

Treatment uptake in the era of quadruple pharmacotherapy for heart failure with reduced ejection fraction: from prescriptions to patient adherence and persistence

Congress Presentation

Reasons for underutilization of medical therapy for heart failure with reduced ejection fraction

Congress Presentation

Overcoming limitations in using the four pillars in the treatment of HFrEF

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources